1. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
- Author
-
Lei Tao, Yue Zhou, Xiangyu Pan, Yuan Luo, Jiahao Qiu, Xia Zhou, Zhiqian Chen, Yan Li, Lian Xu, Yang Zhou, Zeping Zuo, Chunqi Liu, Liang Wang, Xiaocong Liu, Xinyu Tian, Na Su, Zhengnan Yang, Yu Zhang, Kun Gou, Na Sang, Huan Liu, Jiao Zou, Yuzhou Xiao, Xi Zhong, Jing Xu, Xinyu Yang, Kai Xiao, Yanyang Liu, Shengyong Yang, Yong Peng, Junhong Han, Xiaobo Cen, and Yinglan Zhao
- Subjects
Science - Abstract
Abstract Poly (ADP-ribose) polymerase inhibitors (PARPi) are selectively active in ovarian cancer (OC) with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1/2 and other DNA repair pathway members. We sought molecular targeted therapy that induce HRD in HR-proficient cells to induce synthetic lethality with PARPi and extend the utility of PARPi. Here, we demonstrate that lysine-specific demethylase 1 (LSD1) is an important regulator for OC. Importantly, genetic depletion or pharmacological inhibition of LSD1 induces HRD and sensitizes HR-proficient OC cells to PARPi in vitro and in multiple in vivo models. Mechanistically, LSD1 inhibition directly impairs transcription of BRCA1/2 and RAD51, three genes essential for HR, dependently of its canonical demethylase function. Collectively, our work indicates combination with LSD1 inhibitor could greatly expand the utility of PARPi to patients with HR-proficient tumor, warranting assessment in human clinical trials.
- Published
- 2023
- Full Text
- View/download PDF